These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 452843)

  • 21. A community survey of Parkinson's disease.
    Snow B; Wiens M; Hertzman C; Calne D
    CMAJ; 1989 Sep; 141(5):418-22. PubMed ID: 2766181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.
    Zanetti R; Loria D; Rosso S
    Melanoma Res; 2006 Jun; 16(3):201-6. PubMed ID: 16718266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States.
    Lanska DJ
    J Neurol Sci; 1997 Jan; 145(1):105-8. PubMed ID: 9073037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinsonism treated with levodopa: progression and mortality.
    Maier Hoehn MM
    J Neural Transm Suppl; 1983; 19():253-64. PubMed ID: 6583311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa in the treatment of Parkinson's disease.
    Koller WC
    Neurology; 2000; 55(11 Suppl 4):S2-7; discussion S8-12. PubMed ID: 11147506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of chronic levodopa therapy in Parkinson's disease.
    Battistin L; Bracco F; Saladini M
    J Neural Transm Suppl; 1986; 22():201-7. PubMed ID: 3465871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.
    Schrag A; Quinn N
    Brain; 2000 Nov; 123 ( Pt 11)():2297-305. PubMed ID: 11050029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa.
    Esposito F; Tessitore A; Giordano A; De Micco R; Paccone A; Conforti R; Pignataro G; Annunziato L; Tedeschi G
    Brain; 2013 Mar; 136(Pt 3):710-25. PubMed ID: 23423673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 36. Young onset Parkinson's disease.
    Quinn N; Critchley P; Marsden CD
    Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of L-dopa on course of Parkinson's disease.
    Curtis L; Lees AJ; Stern GM; Marmot MG
    Lancet; 1984 Jul; 2(8396):211-2. PubMed ID: 6146763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of deep brain stimulation and levodopa on postural sway in Parkinson's disease.
    Rocchi L; Chiari L; Horak FB
    J Neurol Neurosurg Psychiatry; 2002 Sep; 73(3):267-74. PubMed ID: 12185157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortality of patients with Parkinson's disease treated with levodopa.
    Marttila RJ; Rinne UK; Siirtola T; Sonninen V
    J Neurol; 1977 Oct; 216(3):147-53. PubMed ID: 72132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.